ClinicalTrials.gg
CompletedNCT01457950Updated May 7, 2014Results posted

A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

A Phase 3 interventional study of denosumab and placebo in Osteoporosis, Postmenopausal, sponsored by GlaxoSmithKline. Completed at 10 sites in Korea, Republic of. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-05-07.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
20th of 31
135 · median 278
Started
2011
the only one that year
Phase 3
17 of 31
1 open now
Registered
11th of 31
by date
Lead sponsor
3 of 31
GlaxoSmithKline

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 20th largest by enrollment, is the only one that started in 2011, is one of 17 in phase 3, and was the 11th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 60 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Korean postmenopausal women with osteoporosis.

03

Conditions studied

  • Osteoporosis, Postmenopausal

Keywords

  • denosumab
  • Republic of Korea
  • dual energy x-ray absorptiometry
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory Korean women with osteoporosis
  • greater than 5 years postmenopausal
  • aged 60 to 90 years old
  • absolute bone mineral density value consistent with a T-score less than -2.5 and greater than or equal to - 4.0 at the either the lumbar spine or total hip, as measured by dual energy x-ray absorptiometry. Subjects with a T-score less than -4.0 are at very high risk for fracture and will be excluded.

Exclusion criteria

Exclusion Criteria:

  • previous or current metabolic bone disease, Paget's or Cushing's disease, or hyperprolactinemia
  • current hypo- or hyperparathyroidism or hypo- or hyperthyroidism unless on stable thyroid replacement therapy and TSH level meets criteria
  • rheumatoid arthritis
  • cirrhosis of the liver or unstable liver disease or or AST greater than or equal to 2.0 times the , or alkaline phosphatase and greater than or equal to 1.5 times the upper limit of normal
  • medications used to treat osteoporosis, defined for type and duration of use, and including IV and oral bisphosphonates
  • medications that affect bone metabolism including parathyroid hormone or derivatives; anabolic steroids or testosterone; glucocorticosteroids; systemic hormone replacement therapy; selective estrogen receptor modulators; tibolone, calcitonin, and calcitriol or vitamin D derivatives; other bone active drugs including anticonvulsives (but not benzodiazepines) and heparin; chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, and gonadotropin-releasing hormone agonists
  • within 5 years except certain resected types
  • malabsorption syndrome or gastrointestinal disorders associated with malabsorption
  • abnormal calcium level
  • vitamin D deficiency
  • any laboratory abnormality that will prevent the subject from completing the study or interfere with interpretation of study results
  • severe renal impairment or on dialysis
  • impaired immune system or subject is taking
  • oral or dental conditions including current or past history of osteomyelitis or osteonecrosis of the jaw; active dental or jaw condition with requires oral surgery; planned invasive dental procedure; un-healed dental or oral surgery
  • any disorder that compromises the ability of the subject to give written or to comply with study procedures
  • any physical or psychiatric disorder that will prevent the subject from completing the study or interferes with study results
  • known to have tested positive for
  • less than two lumbar vertebrae evaluable for DXA measurements
  • height, weight, or girth that may preclude accurate DXA measurements
  • drug or alcohol abuse within 12 months that interferes with understanding or completing the study
  • known sensitivity to mammalian cell-derived drug products
  • use of an drug or device within 30 days of enrollment or currently receiving other investigational agent(s)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Arm 1

    denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase

    Drug: denosumab

  • Placebo comparator
    Arm 2

    placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase

    Drug: placebo

  • Experimental
    Arm 3

    open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase

    Drug: open-label denosumab

Interventions

  • double-blind phase: 60mg subcutaneous injection, single dose

  • Drugplacebo

    double-blind phase: placebo subcutaneous injection, single dose

  • Drugopen-label denosumab

    open-label phase: 60mg subcutaneous injection, single dose

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6

    Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using the Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 6 - measure at Baseline) divided by the measure at Baseline \* 100.

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Mean Percent Change From Baseline in Lumbar Spine BMD at Month 1

    Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1 - measure at Baseline) divided by the measure at Baseline \* 100.

    Time frame: Baseline and Month 1

  2. Mean Percent Change From Baseline in Total Hip, Femoral Neck, and Trochanter BMD at Month 1 and Month 6

    Mean percent change from Baseline in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covarience (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1/6 - measure at Baseline) divided by the measure at Baseline \* 100.

    Time frame: Baseline, Month 1 and Month 6

  3. Median Percent Change From Baseline in s-CTX and s-P1NP Biomarkers at Months 1, 3 and 6

    Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Baseline=(measure at post-Baseline - measure at Baseline) divided by measure at Baseline \* 100.

    Time frame: Baseline, Months 1, 3 and 6

  4. Number of Participants With Any Adverse Events (AE) or Any Serious Adverse Events (SAE)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.

    Time frame: From Baseline up to Month 6

  5. Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  6. Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin and Total Protein at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  7. Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  8. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Platelet Count and White Blood Cell Count at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  9. Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine and Uric Acid at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  10. Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, Very Low Density Lipoproteins (VLDL) Cholesterol Calculation at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  11. Change From Baseline in Hematocrit at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  12. Change From Baseline in Mean Corpuscle Hemoglobin at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  13. Change From Baseline in Mean Corpuscular Volume at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  14. Change From Baseline in Red Blood Cell Count at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  15. Change From Baseline in Red Cell Distribution Width at Month 6

    Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  16. Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Month 6

    Vital Sign Changes from Baseline of potential clinical concern for Diastolic Blood Pressure (\<50 or \>120 Bits Per Minutes \[bpm\]), Systolic Blood Pressure (\>170 Millimeters of Mercury \[mmHg\] or \<100 mmHg) and Heart rate (\>110 mmHg or \<50 mmHg) are summarized. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

    Time frame: Baseline and Month 6

  17. Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab

    Number of participants with positive and negative results for both neutralizing antibodies to denosumab, and for binding antibodies to denosumab at Month 6 was summarized.

    Time frame: Month 6

Other outcomes

  1. Mean Percent Change From Baseline in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Denosumab

    Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 12 - measure at Baseline) divided by the measure at Baseline \* 100.

    Time frame: Baseline and Month 12

  2. Mean Percent Change From Month 6 in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Placebo

    Mean percent change from Month 6 in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Month 6 BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by the measure at Month 6 \* 100.

    Time frame: Month 6 and Month 12

  3. Mean Percent Change From Baseline in Total Hip, Femoral Neck, and Trochanter BMD at Month 12 for Participants Previously Randomized to Denosumab

    Mean percent change from Baseline in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 12 - measure at Baseline) divided by the measure at Baseline \* 100.

    Time frame: Baseline and Month 12

  4. Mean Percent Change From Month 6 in Total Hip, Femoral Neck, and Trochanter BMD at Month 12 for Participants Previously Randomized to Placebo

    Mean percent change from Month 6 in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Month 6 BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by the measure at Month 6 \* 100.

    Time frame: Month 6 and Month 12

  5. Median Percent Change From Baseline in s-CTX and s-P1NP Biomarkers at Month 12 for Participants Previously Randomized to Denosumab

    Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Baseline=(measure at post-Baseline - measure at Baseline) divided by measure at Baseline \* 100.

    Time frame: Baseline and Month 12

  6. Median Percent Change From Month 6 in s-CTX and s-P1NP Biomarkers at Month 12 for Participants Previously Randomized to Placebo

    Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by measure at Month 6 \* 100.

    Time frame: Month 6 and Month 12

  7. Number of Participants With Any Adverse Events (AE) or Any Serious Adverse Events (SAE) During the Open-Label Extension Phase

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.

    Time frame: From Month 6 to Month 12

  8. Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  9. Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin and Total Protein at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  10. Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  11. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Platelet Count and White Blood Cell Count at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  12. Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine and Uric Acid at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  13. Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, Very Low Density Lipoproteins (VLDL) Cholesterol Calculation at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  14. Change From Baseline in Hematocrit at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  15. Change From Baseline in Mean Corpuscle Hemoglobin at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  16. Change From Baseline in Red Blood Cell Count at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  17. Change From Baseline in Red Cell Distribution Width at Month 12

    Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  18. Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Month 12

    Vital Sign Changes from Baseline of potential clinical concern for Diastolic Blood Pressure (\<50 or \>120 Bits Per Minutes \[bpm\]), Systolic Blood Pressure (\>170 Millimeters of Mercury \[mmHg\] or \<100 mmHg) and Heart rate (\>110 mmHg or \<50 mmHg) are summarized. Change from Baseline was calculated as the Month 12 value minus the Baseline value.

    Time frame: Baseline and Month 12

  19. Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab at Month 12

    Number of participants with positive and negative results for both neutralizing antibodies to denosumab, and for binding antibodies to denosumab at Month 12 was summarized.

    Time frame: Month 12

07

Results

Posted Oct 29, 2013

Participant flow

Double-Blind Phase
Participant flow — Double-Blind Phase
MilestoneDenosumab 60 mgPlaceboDenosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Started696600
Completed the 6 month assessment626400
Completed606300
Not completed9300
Withdrew: Continuation criteria not met1000
Withdrew: Protocol violation2100
Withdrew: Withdrawal by subject6200
Open-Label Phase
Participant flow — Open-Label Phase
MilestoneDenosumab 60 mgPlaceboDenosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Started006063
Completed005861
Not completed0022
Withdrew: Adverse event0001
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject0020

Outcome measures

PrimaryMean Percent Change From Baseline in Lumbar Spine BMD at Month 6

Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using the Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 6 - measure at Baseline) divided by the measure at Baseline \* 100.

Time frame:
Baseline and Month 6
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6
Percent changeDenosumab 60 mgPlacebo
Mean Percent Change From Baseline in Lumbar Spine BMD at Month 64.10 ± 0.4070.89 ± 0.413
Statistical analysis
  • Denosumab 60 mg vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): 3.21 · 95% CI 2.06 to 4.36
SecondaryMean Percent Change From Baseline in Lumbar Spine BMD at Month 1

Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1 - measure at Baseline) divided by the measure at Baseline \* 100.

Time frame:
Baseline and Month 1
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Lumbar Spine BMD at Month 1
Percent changeDenosumab 60 mgPlacebo
Mean Percent Change From Baseline in Lumbar Spine BMD at Month 11.35 ± 0.3750.62 ± 0.380
SecondaryMean Percent Change From Baseline in Total Hip, Femoral Neck, and Trochanter BMD at Month 1 and Month 6

Mean percent change from Baseline in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covarience (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1/6 - measure at Baseline) divided by the measure at Baseline \* 100.

Time frame:
Baseline, Month 1 and Month 6
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Total Hip, Femoral Neck, and Trochanter BMD at Month 1 and Month 6
Percent changeDenosumab 60 mgPlacebo
Total hip, Month 1, n=67, 630.74 ± 0.2380.05 ± 0.245
Total hip, Month 6, n=69, 642.23 ± 0.2450.57 ± 0.254
Femoral neck, Month 1, n=67, 631.30 ± 0.344-0.04 ± 0.354
Fermoral neck, Month 6, n=69, 642.23 ± 0.3300.84 ± 0.343
Trochanter, Month 1, n=67, 630.82 ± 0.3800.39 ± 0.392
Trochanter, Month n =69, 642.66 ± 0.4180.67 ± 0.434
SecondaryMedian Percent Change From Baseline in s-CTX and s-P1NP Biomarkers at Months 1, 3 and 6

Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Baseline=(measure at post-Baseline - measure at Baseline) divided by measure at Baseline \* 100.

Time frame:
Baseline, Months 1, 3 and 6
Reported as:
Median · Percent change
Median Percent Change From Baseline in s-CTX and s-P1NP Biomarkers at Months 1, 3 and 6
Percent changeDenosumab 60 mgPlacebo
s-CTx, Month 1, n=69, 66-80.72 (-88.62 to -73.50)-14.48 (-33.58 to -1.08)
s-CTx, Month 3, n=68, 65-82.23 (-89.00 to -73.67)-27.49 (-44.85 to -5.13)
s-CTx, Month 6, n=60, 63-74.32 (-84.09 to -65.33)-21.21 (-37.41 to 3.44)
s-PINP, Month 1, n=69, 66-18.75 (-35.71 to -6.00)-4.65 (-17.86 to 9.68)
s-PINP, Month 3, n=68, 65-77.1 (-83.54 to -68.57)-21.57 (-38.89 to -6.35)
s-PINP, Month 6, n=60, 63-76.18 (-81.27 to -61.89)-21.05 (-42.42 to -6.67)
SecondaryNumber of Participants With Any Adverse Events (AE) or Any Serious Adverse Events (SAE)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.

Time frame:
From Baseline up to Month 6
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AE) or Any Serious Adverse Events (SAE)
ParticipantsDenosumab 60 mgPlacebo
Any AE3832
Any SAE72
SecondaryChange From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · Ratio
Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 6
RatioDenosumab 60 mgPlacebo
Albumin/globulin ratio, n=60, 630.020 ± 0.14240.052 ± 0.1390
BUN/creatinine ratio, n=60, 63-7.917 ± 25.2917-4.063 ± 27.3436
SecondaryChange From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin and Total Protein at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · Grams (G)/Liter (L)
Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin and Total Protein at Month 6
Grams (G)/Liter (L)Denosumab 60 mgPlacebo
Albumin, n=60,630.217 ± 1.89640.365 ± 2.2598
Hemoglobin, n=59, 631.153 ± 5.82741.778 ± 5.6894
Mean corpuscle hemoglobin concentration, n=59, 63-5.186 ± 9.9264-6.857 ± 9.4593
Total protein, n=60, 63-0.050 ± 2.9939-0.127 ± 3.3864
SecondaryChange From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · Internationational Units(IU)/Liter (L)
Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Month 6
Internationational Units(IU)/Liter (L)Denosumab 60 mgPlacebo
Alkaline phosphatase, n=60, 63-24.283 ± 15.9513-8.222 ± 11.2127
Alanine amino transferase, n=60, 632.117 ± 6.4047-0.397 ± 8.8035
Aspartate amino transferase, n=59, 631.034 ± 4.4527-0.032 ± 7.4962
Creatine kinase, n=60, 637.617 ± 51.66583.905 ± 31.2052
Gamma glutamyl transferase, n=60, 63-0.133 ± 8.4381-2.143 ± 7.9532
Lactate dehydraogenase, n=59, 636.119 ± 18.11563.889 ± 20.4979
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Platelet Count and White Blood Cell Count at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · 10^9 cells per liter (GI/L)
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Platelet Count and White Blood Cell Count at Month 6
10^9 cells per liter (GI/L)Denosumab 60 mgPlacebo
Basophils, n=58, 63-0.003 ± 0.0131-0.006 ± 0.0165
Eosinophils, n=58, 63-0.019 ± 0.1254-0.033 ± 0.1309
Lymphocytes, n=58, 63-0.047 ± 0.4096-0.206 ± 0.5930
Monocytes, n=58, 63-0.033 ± 0.1094-0.059 ± 0.1324
Segmented neutrophils, n=58, 630.114 ± 1.3382-0.213 ± 1.0934
Total neutrophils, n=58, 630.114 ± 1.3382-0.213 ± 1.0934
Platelet count, n=58, 631.621 ± 31.7881-6.190 ± 35.7874
White blood cell count, n=58, 630.014 ± 1.4026-0.517 ± 1.2003
SecondaryChange From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine and Uric Acid at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · Micromole/liter (UMOL/L)
Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine and Uric Acid at Month 6
Micromole/liter (UMOL/L)Denosumab 60 mgPlacebo
Direct bilirubin, n=60, 630.300 ± 1.03010.222 ± 1.1974
Indirect bilirubin, n=60, 631.567 ± 3.47570.508 ± 3.5372
Total bilirubin, n=60, 631.867 ± 3.89470.730 ± 3.8404
Creatinine, n=60, 632.037 ± 6.49160.940 ± 5.1644
Uric acid, n=60, 6311.500 ± 38.96220.159 ± 40.9757
SecondaryChange From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, Very Low Density Lipoproteins (VLDL) Cholesterol Calculation at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · Millimole/Liter (MMOL/L)
Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, Very Low Density Lipoproteins (VLDL) Cholesterol Calculation at Month 6
Millimole/Liter (MMOL/L)Denosumab 60 mgPlacebo
Calcium (corrected), n=1, 10.110 ± NA0.000 ± NA
Calcium, n=59, 63-0.020 ± 0.08900.002 ± 0.0768
Chloride, n=60, 63-0.200 ± 2.29810.444 ± 2.3264
Glucose, n=60, 63-0.873 ± 2.5458-0.567 ± 1.2118
Potassium, n=59, 630.000 ± 0.39000.060 ± 0.3476
Magnesium, n=60, 630.004 ± 0.05850.009 ± 0.0462
Sodium, n=60, 63-0.400 ± 2.12490.095 ± 1.9486
Phosphorus inorganic, n=60, 63-0.072 ± 0.1505-0.063 ± 0.1695
Triglycerides, n=60, 63-0.166 ± 0.7155-0.156 ± 0.6119
Urea/BUN, n=60, 63-0.258 ± 1.1878-0.119 ± 1.4134
VLDL cholesterol calculation, n=59, 63-0.098 ± 0.2844-0.072 ± 0.2810
SecondaryChange From Baseline in Hematocrit at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · Proportion of RBCs in blood
Change From Baseline in Hematocrit at Month 6
Proportion of RBCs in bloodDenosumab 60 mgPlacebo
Change From Baseline in Hematocrit at Month 60.009 ± 0.01960.013 ± 0.0196
SecondaryChange From Baseline in Mean Corpuscle Hemoglobin at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · Picograms (PG)/cell
Change From Baseline in Mean Corpuscle Hemoglobin at Month 6
Picograms (PG)/cellDenosumab 60 mgPlacebo
Change From Baseline in Mean Corpuscle Hemoglobin at Month 60.068 ± 0.71110.146 ± 0.6696
SecondaryChange From Baseline in Mean Corpuscular Volume at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · Femtoliters (FL)
Change From Baseline in Mean Corpuscular Volume at Month 6
Femtoliters (FL)Denosumab 60 mgPlacebo
Change From Baseline in Mean Corpuscular Volume at Month 61.695 ± 2.50002.397 ± 2.6368
SecondaryChange From Baseline in Red Blood Cell Count at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · 10^12 cells per liter (TI/L)
Change From Baseline in Red Blood Cell Count at Month 6
10^12 cells per liter (TI/L)Denosumab 60 mgPlacebo
Change From Baseline in Red Blood Cell Count at Month 60.025 ± 0.18440.037 ± 0.1920
SecondaryChange From Baseline in Red Cell Distribution Width at Month 6

Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Mean · percentage (%) of mean RBC volume
Change From Baseline in Red Cell Distribution Width at Month 6
percentage (%) of mean RBC volumeDenosumab 60 mgPlacebo
Change From Baseline in Red Cell Distribution Width at Month 60.475 ± 1.02560.556 ± 0.9242
SecondaryNumber of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Month 6

Vital Sign Changes from Baseline of potential clinical concern for Diastolic Blood Pressure (\<50 or \>120 Bits Per Minutes \[bpm\]), Systolic Blood Pressure (\>170 Millimeters of Mercury \[mmHg\] or \<100 mmHg) and Heart rate (\>110 mmHg or \<50 mmHg) are summarized. Change from Baseline was calculated as the Month 6 value minus the Baseline value.

Time frame:
Baseline and Month 6
Reported as:
Number · Participants
Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Month 6
ParticipantsDenosumab 60 mgPlacebo
Diastolic blood pressure, Low, n=60, 6302
Systolic blood pressure, High, n=60, 6312
Systolic blood pressure, Low, n=60, 6311
Heart rate, High, n=60, 6300
Heart rate, Low, n=60, 6300
SecondaryNumber of Participants With Positive and Negative Results for Anti-body Formation to Denosumab

Number of participants with positive and negative results for both neutralizing antibodies to denosumab, and for binding antibodies to denosumab at Month 6 was summarized.

Time frame:
Month 6
Reported as:
Number · Participants
Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab
ParticipantsDenosumab 60 mgPlacebo
Neutralizing antibodies, Positive, n=0, 0NANA
Neutralizing antibodies, Negative, n=0, 0NANA
Binding antibodies, Positive, n=60, 6300
Binding antibodies, Negative, n=60, 636063
Other pre-specifiedMean Percent Change From Baseline in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Denosumab

Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 12 - measure at Baseline) divided by the measure at Baseline \* 100.

Time frame:
Baseline and Month 12
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Denosumab
Percent changeDenosumab 60 mg to Open-Label Denosumab 60mg
Mean Percent Change From Baseline in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Denosumab5.62 ± 3.776
Other pre-specifiedMean Percent Change From Month 6 in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Placebo

Mean percent change from Month 6 in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Month 6 BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by the measure at Month 6 \* 100.

Time frame:
Month 6 and Month 12
Reported as:
Mean · Percent change
Mean Percent Change From Month 6 in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Placebo
Percent changePlacebo to Open-Label Denosumab 60 mg
Mean Percent Change From Month 6 in Lumbar Spine BMD at Month 12 for Participants Previously Randomized to Placebo2.67 ± 3.440
Other pre-specifiedMean Percent Change From Baseline in Total Hip, Femoral Neck, and Trochanter BMD at Month 12 for Participants Previously Randomized to Denosumab

Mean percent change from Baseline in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 12 - measure at Baseline) divided by the measure at Baseline \* 100.

Time frame:
Baseline and Month 12
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Total Hip, Femoral Neck, and Trochanter BMD at Month 12 for Participants Previously Randomized to Denosumab
Percent changeDenosumab 60 mg to Open-Label Denosumab 60mg
Total hip3.07 ± 2.476
Femoral neck3.39 ± 3.158
Trochanter3.39 ± 4.653
Other pre-specifiedMean Percent Change From Month 6 in Total Hip, Femoral Neck, and Trochanter BMD at Month 12 for Participants Previously Randomized to Placebo

Mean percent change from Month 6 in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Month 6 BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by the measure at Month 6 \* 100.

Time frame:
Month 6 and Month 12
Reported as:
Mean · Percent change
Mean Percent Change From Month 6 in Total Hip, Femoral Neck, and Trochanter BMD at Month 12 for Participants Previously Randomized to Placebo
Percent changePlacebo to Open-Label Denosumab 60 mg
Total hip1.46 ± 1.701
Femoral neck1.12 ± 2.668
Trochanter2.13 ± 2.762
Other pre-specifiedMedian Percent Change From Baseline in s-CTX and s-P1NP Biomarkers at Month 12 for Participants Previously Randomized to Denosumab

Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Baseline=(measure at post-Baseline - measure at Baseline) divided by measure at Baseline \* 100.

Time frame:
Baseline and Month 12
Reported as:
Median · Percent change
Median Percent Change From Baseline in s-CTX and s-P1NP Biomarkers at Month 12 for Participants Previously Randomized to Denosumab
Percent changeDenosumab 60 mg to Open-Label Denosumab 60mg
s-CTx-63.36 (-77.14 to -48.62)
s-PINP-78.00 (-84.31 to -66.67)
Other pre-specifiedMedian Percent Change From Month 6 in s-CTX and s-P1NP Biomarkers at Month 12 for Participants Previously Randomized to Placebo

Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Month 6=(measure at Month 12 - measure at Month 6) divided by measure at Month 6 \* 100.

Time frame:
Month 6 and Month 12
Reported as:
Median · Percent change
Median Percent Change From Month 6 in s-CTX and s-P1NP Biomarkers at Month 12 for Participants Previously Randomized to Placebo
Percent changePlacebo to Open-Label Denosumab 60 mg
s-CTx-50.90 (-71.95 to -24.05)
s-PINP-66.67 (-76.82 to -55.65)
Other pre-specifiedNumber of Participants With Any Adverse Events (AE) or Any Serious Adverse Events (SAE) During the Open-Label Extension Phase

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.

Time frame:
From Month 6 to Month 12
Reported as:
Number · Participants
Number of Participants With Any Adverse Events (AE) or Any Serious Adverse Events (SAE) During the Open-Label Extension Phase
ParticipantsDenosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Any AE2229
Any SAE13
Other pre-specifiedChange From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · Ratio
Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 12
RatioDenosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Albumin/globulin ratio, n=58, 600.016 ± 0.14730.032 ± 0.1621
BUN/creatinine ratio, n=58, 60-5.776 ± 24.42972.500 ± 27.7962
Other pre-specifiedChange From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin and Total Protein at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · Grams (G)/Liter (L)
Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin and Total Protein at Month 12
Grams (G)/Liter (L)Denosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Albumin, n=58, 600.293 ± 2.11100.450 ± 1.9866
Hemoglobin, n=56, 601.411 ± 5.78332.033 ± 6.0084
Mean corpuscle hemoglobin concentration, n=56, 60-5.679 ± 6.6143-6.650 ± 7.7587
Total protein, n=58, 600.224 ± 3.49460.267 ± 2.8216
Other pre-specifiedChange From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · Internationational Units(IU)/Liter (L)
Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Month 12
Internationational Units(IU)/Liter (L)Denosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Alkaline phosphatase, n=58, 60-25.603 ± 14.4780-23.767 ± 15.7570
Alanine amino transferase, n=58, 601.810 ± 7.9922-0.150 ± 8.9288
Aspartate amino transferase, n=58, 600.879 ± 6.4293-0.467 ± 6.2666
Creatine kinase, n=58, 60-4.534 ± 44.06904.500 ± 52.0731
Gamma glutamyl transferase, n=58, 600.4823 ± 6.9541-0.600 ± 9.4961
Lactate dehydraogenase, n=58, 60-0.552 ± 19.2237-1.217 ± 24.7243
Other pre-specifiedChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Platelet Count and White Blood Cell Count at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · 10^9 cells per liter (GI/L)
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Platelet Count and White Blood Cell Count at Month 12
10^9 cells per liter (GI/L)Denosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Basophils, n=54, 59-0.004 ± 0.0164-0.002 ± 0.0148
Eosinophils, n=54, 590.024 ± 0.14890.019 ± 0.1860
Lymphocytes, n=54, 590.098 ± 0.4436-0.089 ± 0.5599
Monocytes, n=54, 59-0.009 ± 0.1053-0.039 ± 0.1443
Segmented neutrophils, n=54, 590.014 ± 1.1748-0.259 ± 1.2035
Total neutrophils, n=54, 590.014 ± 1.1748-0.259 ± 1.2035
Platelet count, n=55, 60-4.018 ± 34.8215-4.233 ± 37.7913
White blood cell count, n=54, 590.122 ± 1.1618-0.369 ± 1.3903
Other pre-specifiedChange From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine and Uric Acid at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · Micromole/liter (UMOL/L)
Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine and Uric Acid at Month 12
Micromole/liter (UMOL/L)Denosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Direct bilirubin, n=58, 600.241 ± 1.35480.100 ± 1.2980
Indirect bilirubin, n=58, 601.034 ± 4.03910.800 ± 3.3385
Total bilirubin, n=58, 601.276 ± 4.65960.900 ± 3.5401
Creatinine, n=58, 600.948 ± 5.1157-0.015 ± 4.6216
Uric acid, n=58, 604.483 ± 41.38702.000 ± 44.0647
Other pre-specifiedChange From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, Very Low Density Lipoproteins (VLDL) Cholesterol Calculation at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · Millimole/Liter (MMOL/L)
Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, Very Low Density Lipoproteins (VLDL) Cholesterol Calculation at Month 12
Millimole/Liter (MMOL/L)Denosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Calcium (corrected), n=0, 0NA ± NANA ± NA
Calcium, n=58, 60-0.031 ± 0.0944-0.004 ± 0.0904
Chloride, n=58, 600.328 ± 2.55730.300 ± 2.4446
Glucose, n=58, 60-0.760 ± 2.9331-0.500 ± 1.2985
Potassium, n=58, 600.047 ± 0.43980.045 ± 0.3078
Magnesium, n=58, 600.009 ± 0.06790.004 ± 0.0514
Sodium, n=58, 60-0.172 ± 2.15320.067 ± 2.2986
Phosphorus inorganic, n=58, 60-0.153 ± 0.1530-0.094 ± 0.1981
Triglycerides, n=58, 60-0.144 ± 0.7716-0.033 ± 0.8449
Urea/BUN, n=58, 60-0.233 ± 1.21830.158 ± 1.5771
VLDL cholesterol calculation, n=58, 59-0.066 ± 0.3539-0.044 ± 0.3234
Other pre-specifiedChange From Baseline in Hematocrit at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · Proportion of RBCs in blood
Change From Baseline in Hematocrit at Month 12
Proportion of RBCs in bloodDenosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Change From Baseline in Hematocrit at Month 120.010 ± 0.01820.014 ± 0.0185
Other pre-specifiedChange From Baseline in Mean Corpuscle Hemoglobin at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · Picograms (PG)/cell)
Change From Baseline in Mean Corpuscle Hemoglobin at Month 12
Picograms (PG)/cell)Denosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Change From Baseline in Mean Corpuscle Hemoglobin at Month 12-0.304 ± 0.7632-0.310 ± 0.5058
Other pre-specifiedChange From Baseline in Red Blood Cell Count at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · 10^12 cells per liter (TI/L)
Change From Baseline in Red Blood Cell Count at Month 12
10^12 cells per liter (TI/L)Denosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Change From Baseline in Red Blood Cell Count at Month 120.086 ± 0.16340.103 ± 0.1904
Other pre-specifiedChange From Baseline in Red Cell Distribution Width at Month 12

Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Mean · percentage (%) of mean RBC volume
Change From Baseline in Red Cell Distribution Width at Month 12
percentage (%) of mean RBC volumeDenosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Change From Baseline in Red Cell Distribution Width at Month 120.007 ± 0.78970.203 ± 0.8718
Other pre-specifiedNumber of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Month 12

Vital Sign Changes from Baseline of potential clinical concern for Diastolic Blood Pressure (\<50 or \>120 Bits Per Minutes \[bpm\]), Systolic Blood Pressure (\>170 Millimeters of Mercury \[mmHg\] or \<100 mmHg) and Heart rate (\>110 mmHg or \<50 mmHg) are summarized. Change from Baseline was calculated as the Month 12 value minus the Baseline value.

Time frame:
Baseline and Month 12
Reported as:
Number · Participants
Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Month 12
ParticipantsDenosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Diastolic blood pressure, High01
Diastolic blood pressure, Low20
Systolic blood pressure, High02
Systolic blood pressure, Low02
Heart rate, High00
Heart rate, Low00
Other pre-specifiedNumber of Participants With Positive and Negative Results for Anti-body Formation to Denosumab at Month 12

Number of participants with positive and negative results for both neutralizing antibodies to denosumab, and for binding antibodies to denosumab at Month 12 was summarized.

Time frame:
Month 12
Reported as:
Number · Participants
Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab at Month 12
ParticipantsDenosumab 60 mg to Open-Label Denosumab 60mgPlacebo to Open-Label Denosumab 60 mg
Neutralizing antibodies, Positive, n=0, 0NANA
Neutralizing antibodies, Negative, n=0, 0NANA
Binding antibodies, Positive, n=58, 6100
Binding antibodies, Negative, n=58, 615861

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study medication to the end of the Open-Label Phase (up to Month 12).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Phase: Denosumab 60 mg—7/69 (10.1%)13/69 (18.8%)
Randomized Phase: Placebo—2/66 (3%)11/66 (16.7%)
Open Label Denosumab 60 mg (Previously Randomized Denosumab)—1/60 (1.7%)12/60 (20%)
Open Label Denosumab 60 mg (Previously Randomized Placebo)—3/63 (4.8%)7/63 (11.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventRandomized Phase: Denosumab 60 mgRandomized Phase: PlaceboOpen Label Denosumab 60 mg (Previously Randomized Denosumab)Open Label Denosumab 60 mg (Previously Randomized Placebo)
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders2/690/660/600/63
Macular holeEye disorders0/690/661/600/63
Spinal compression fractureInjury, poisoning and procedural complications0/690/660/601/63
Appendicitis perforatedInfections and infestations0/690/660/601/63
Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/690/660/601/63
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/691/660/600/63
AppendicitisInfections and infestations0/691/660/600/63
BronchitisInfections and infestations1/690/660/600/63
HaemorrhoidsGastrointestinal disorders1/690/660/600/63
Tendon ruptureInjury, poisoning and procedural complications1/690/660/600/63
Most frequent other events
Most frequent other events
EventRandomized Phase: Denosumab 60 mgRandomized Phase: PlaceboOpen Label Denosumab 60 mg (Previously Randomized Denosumab)Open Label Denosumab 60 mg (Previously Randomized Placebo)
NasopharyngitisInfections and infestations4/698/666/606/63
ConstipationGastrointestinal disorders5/692/660/600/63
MyalgiaMusculoskeletal and connective tissue disorders4/691/660/600/63
DyspepsiaGastrointestinal disorders0/690/663/601/63
GastritisGastrointestinal disorders0/690/663/600/63
Ligament sprainInjury, poisoning and procedural complications0/690/663/601/63

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Denosumab 60 mgPlaceboTotal
Mean67.0 ± 4.8666.0 ± 4.7766.5 ± 4.83
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab 60 mgPlaceboTotal
Female6966135
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Denosumab 60 mgPlaceboTotal
Asian - East Asian Heritage6966135
08

Study locations

10 sites
  • GSK Investigational Site
    Busan, 602-739, Korea, Republic of
  • GSK Investigational Site
    Daegu, Korea, Republic of
  • GSK Investigational Site
    Gwangju, 501-757, Korea, Republic of
  • GSK Investigational Site
    Seoul, 100-380, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 120-752, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    songpa-gu, Seoul, 138-736, Korea, Republic of
  • GSK Investigational Site
    Suwon, 443-721, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Dec 2012 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2011
First posted
Oct 24, 2011
Start
Nov 2011
Primary completionActual
Dec 2012
CompletionActual
Jun 2013
Results first posted
Oct 29, 2013
Last update
May 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01457950
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 24, 2011
Start date
Nov 2011
Primary completion
Dec 2012
Completion
Jun 2013
Results posted
Oct 29, 2013
Last update
May 7, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion